Targeting Strategies for Aberrant Lipid Metabolism Reprogramming and the Immune Microenvironment in Esophageal Cancer: A Review

• Published in: Journal of oncology Vol. 2022; pp. 1 - 27
• Main Authors: Cui, Meng-Ying, Yi, Xing, Cao, Zhen-Zhen, Zhu, Dan-Xia, Wu, Jun
• Format: Journal Article
• Language: English
• Published: Egypt Hindawi 05.09.2022; John Wiley & Sons, Inc
• Subjects: Amino acids; Cancer; Cancer therapies; Chemotherapy; Development and progression; Esophageal cancer; Fatty acids; Gastroesophageal reflux; Genes; Health aspects; Hyperplasia; Industrialized nations; Lipids; Medical prognosis; Metabolism; Oncology, Experimental; Oxidation; Physiological aspects; Review; Treatment resistance; Tumors; Canada
• ISSN: 1687-8450; 1687-8450
• DOI: 10.1155/2022/4257359

Esophageal cancer is of high importance to occurrence, development, and treatment resistance. As evidenced by recent studies, pathways (e.g., Wnt/β-catenin, AMPK, and Hippo) are critical to the proliferation, differentiation, and self-renewal of esophageal cancer. In addition, the above pathways play a certain role in regulating esophageal cancer and act as potential therapeutic targets. Over the past few years, the function of lipid metabolism in controlling tumor cells and immune cells has aroused extensive attention. It has been reported that there are intricate interactions between lipid metabolism reprogramming between immune and esophageal cancer cells, whereas molecular mechanisms should be studied in depth. Immune cells have been commonly recognized as a vital player in the esophageal cancer microenvironment, having complex crosstalk with cancer cells. It is increasingly evidenced that the function of immune cells in the tumor microenvironment (TME) is significantly correlated with abnormal lipid metabolism. In this review, the latest findings in lipid metabolism reprogramming in TME are summarized, and the above findings are linked to esophageal cancer progression. Aberrant lipid metabolism and associated signaling pathways are likely to serve as a novel strategy to treat esophageal cancer through lipid metabolism reprogramming.